Compare Dollar Tree, Inc. (DLTR) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Davita Inc — how do they compare? Dollar Tree, Inc. trades at $118.62 (market cap $21.82B), while Davita Inc trades at $175.04 (market cap $11.29B). The key difference: Dollar Tree, Inc. is the larger of the two by market cap, and Davita Inc is more actively traded (582,204 versus 1,613,659). Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Davita Inc for 113 Days on average.
| DLTR | DVA | |
|---|---|---|
Market Cap | $21.82B | $11.29B |
Volume | 1,613,659 | 582,204 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $240.96 |
52-Week Low | $86.80 | $103.87 |
Typical Hold Time | 58 Days | 113 Days |
Enterprise Value | $28.43B | $24.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $116.3, up slightly by 0.09% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $2.70 significantly exceeding the $1.15 estimate. Revenue for 2025 was $17.58 billion, though net income was negative due to a large tax expense, while 2026 projections indicate a return to profitability. Strategic initiatives like store expansions and a multi-price strategy are driving growth, supported by positive institutional buying activity.
The outlook for DLTR is positive, with a consensus price target of $139.33 offering ~20% upside. Key opportunities include continued earnings momentum and market share gains, but risks involve margin pressures from tariffs and rising costs. Investors should weigh the strong ROE of 45.87% against volatility in net income and competitive discount retail dynamics.
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
